This is a preview of subscription content, log in via an institution to check access.
Reference
Pietanza MC, et al. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. PharmacoEconomics : 4 Dec 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0752-0
Rights and permissions
About this article
Cite this article
Pembrolizumab reduces AEs, improves quality-adjusted survival. PharmacoEcon Outcomes News 818, 25 (2018). https://doi.org/10.1007/s40274-018-5523-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5523-9